comprehensive -WSS

comprehensive

author：knowledge 2025-10-02 17:26:53 - browse：997

Eli Lilly headquarters in Indianapolis – pharmaceutical coverage from STAT — Darron Cummings/AP

LONDON — A U.K. government agency on Tuesday said that it won’t recommend Eli Lilly’s Mounjaro — part of a new class of medications that help patients lose weight — for people with type 2 diabetes without additional evidence.

Mounjaro, also known as tirzepatide, has U.S. approval for type 2 diabetes and is expected to win the regulatory green light for obesity later this year. It is one of several medications, along with Wegovy and Ozempic from Novo Nordisk, that have shown dramatic weight loss results, creating a surge in demand and blockbuster sales expectations.

But in draft guidance, the U.K.’s National Institute for Health and Care Excellence, which assesses the cost-effectiveness of medications, said it had asked Lilly for more data “to address the uncertainties in the clinical evidence, when compared to all relevant alternative treatments.” NICE recommendations are used by the National Health Service to determine whether to provide certain medications.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： New Eli Lilly Alzheimer’s data poses Medicare coverage conundrum
Next article： Life sciences deals on track to hit lowest point since 2017

explore

hotspot

WSS

After Optum profits sink, UnitedHealth makes changes

Illumina slashes 2023 revenue projections yet again

European regulators consider appeal over Amylyx ALS drug

Medicare to cover more brain scans related to Alzheimer’s drugs

Readout LOUD podcast: Merger Mondays, Ozempic panic

Female surgeons have lower rates of long

Wikipedia

comprehensive

hotspot

The cancer drug shortage isn’t new — and neither are the solutions

Timeline: How the deadly wildfires took over Maui day by day

Psychedelics group wrestles with new pharma identity

Aspartame and sugar

Supreme Court strikes down use of affirmative action

Biogen’s boardroom scandal saddles CEO with first crisis

In age of alternative facts, a scholarly course on calling out crap

Timeline: How the deadly wildfires took over Maui day by day

New Eli Lilly Alzheimer’s data poses Medicare coverage conundrum

Mark Cuban is blaming the wrong people for high drug costs

Wikipedia

Indictment alleges Trump's ex

UnitedHealth’s Q3 profit jumps as medical costs rise more slowly

Idaho college killings prosecutors challenge defense's grand jury claims

Dozens dead from Maui wildfires: What we know about the victims

Kidney disease boosts cardiac arrest risk for Hispanics, Latinos

Takeaways from AdvaMed, the largest medical devices conference

explore

explore

hotspot

Wikipedia